Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a phase 3 trial. Caplyta ...
Correspondence to Professor Christian Kopkow, Department für Angewandte Gesundheitswissenschaften, Hochschule für Gesundheit (University of Applied Sciences), Gesundheitscampus 6–8, Bochum 44801, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback